A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients
NCT01588769
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
23
Enrollment
INDUSTRY
Sponsor class
Conditions
Glioblastoma Multiforme
Interventions
BIOLOGICAL:
ALECSAT cell based immunotherapy
Sponsor
CytoVac A/S